Plucky founders, not Indian pharma giants, could reshape drug discovery in its new ‘golden age’
The post Plucky founders, not Indian pharma giants, could reshape drug discovery in its new ‘golden age’ appeared first on The Ken .
ImmunitoAI, a startup co-founded by Aridni Shah and Trisha Chatterjee, is challenging the conventional drug discovery methods in the Indian market, which is known for its harsh economic conditions and regulatory environment. The duo's innovative approach involves designing drugs before initiating the discovery process, a unique strategy that has yielded functional drug candidates in a mere five months.
This method, known as "design over discovery," sets ImmunitoAI apart from other players in the field. The company's rapid success contrasts sharply with the usual slow pace of drug discovery, where 90% of successful molecules eventually fail in clinical trials. As AI talent, computational resources, and capital pour into the sector, ImmunitoAI's approach underscores the potential of AI in transforming drug discovery.
The global pipeline of AI-discovered drugs has reached 850, a testament to the growing interest and investment in this area. Major players like Google, Anthropic, OpenAI, and even LinkedIn's Reid Hoffman are not just watching but actively participating in this AI-driven revolution. With the US regulator also embracing AI, the future of drug discovery looks more promising than ever before.
Written by urgent.news from The Ken's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
